Purple Biotech (PPBT) has released an update.
Purple Biotech has announced promising interim results from a Phase 2 pancreatic cancer study, indicating that CM24 combined with nivolumab and chemotherapy could significantly improve survival rates. The study suggests that lower serum myeloperoxidase (MPO) levels may predict better overall survival outcomes, and further results are anticipated in the latter half of 2024. Investors and stakeholders can expect a comprehensive discussion during a virtual event scheduled for July 11, 2024.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
